SPRINGFIELD, Ill. (WAND) — A state Democratic bill to make it faster to receive some HIV medication passed the Illinois House ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and four million HIV-negative people in the country would need to use the jab ...

From the column: "This is a four-alarm fire. ... Let’s take a page from the early days of HIV advocacy and remember, silence ...

The U.S. Supreme Court is gearing up to hear Kennedy v. Braidwood Management Inc., a case that could effectively sever access to cost-free preventive care services — including PrEP.

Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other institutions, have successfully ...

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based ...

12,13 About APRETUDE APRETUDE (Cabotegravir extended-release injectable suspension) is the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option proven superior to daily ...

referring to the network that helped lead to the development of pre-exposure prophylaxis, or PrEP, which people at risk for HIV can take to prevent infection. Other ongoing studies funded by the ...

The decision to reimburse APRETUDE through the NIHB Program will have a meaningful impact on HIV prevention efforts for eligible First Nations and Inuit people who are at-risk of HIV and could ...

Right now, pre-exposure prophylaxis, or PrEP, revenues account for roughly 8% of Gilead’s total revenues, though a smaller portion of that is from Medicaid patients, the analyst tells investors.